secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001140361-25-020157
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre's Hydronidone meets Phase 3 primary endpoint with 52.85% fibrosis regression vs 29.84% placebo (p=0.0002)
--------------------------------------------------------------------------------

- Phase 3 trial met primary endpoint: ≥1-stage Ishak fibrosis regression at Week 52 (52.85% vs 29.84%, p=0.0002).
- NDA submission to China's NMPA expected in Q3 2025; Breakthrough Therapy designation granted in 2021.
- U.S. Phase 2 trial in MASH-associated fibrosis to begin in 2H2025; IND planned for Q3 2025.
- Safety comparable to placebo: 4.88% serious AEs vs 6.45%; no discontinuations due to AEs.
- 248 patients enrolled across 39 hospitals in China; key secondary endpoint also statistically significant (p=0.0246).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125020157/0001140361-25-020157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125020157/ef20048898_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-020157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer